Syndax Insider: Director Exercises $7.20 Options, Sells Shares at $13.30–$16.00
Rhea-AI Filing Summary
Dennis Podlesak, a director of Syndax Pharmaceuticals, reported option exercises and planned sales under a Rule 10b5-1 plan in mid-August 2025. On 08/14/2025, 08/15/2025 and 08/18/2025 he exercised options with a $7.20 strike to acquire blocks of 19,200, 19,200 and 19,200 shares respectively, and contemporaneously reported sales of those shares under the 10b5-1 plan at prices that ranged across the transactions: $13.30–$16.00 (detailed ranges per date provided). Following the reported transactions the Form 4 shows 210,963 shares beneficially owned after acquisitions and 191,763 after sales, and the filer notes he holds 135,000 vested, exercisable options remaining.
Positive
- Transactions executed under a Rule 10b5-1 plan, which provides an affirmative defense against insider trading allegations
- Sales realized prices well above the $7.20 exercise price (reported ranges $13.30–$16.00), indicating proceeds exceeded strike cost
Negative
- Insider sales reduced direct beneficial ownership from 210,963 to 191,763 shares as reported after the transactions
- No operational or financial context is provided in the filing to explain the timing or rationale beyond the 10b5-1 plan
Insights
TL;DR: Routine insider option exercises and planned sales under a 10b5-1 plan; no new material corporate developments disclosed.
These transactions reflect non-derivative share purchases via option exercises at a $7.20 strike and immediate sales executed under a pre-established Rule 10b5-1 plan. The reported sale price ranges ($13.30–$16.00) suggest the sales realized material premiums over the exercise price, but the Form 4 contains no operational or financial results to change company valuation. For investors, this is a disclosure of insider liquidity rather than a signal of corporate performance.
TL;DR: Transactions were executed under a documented 10b5-1 plan, indicating compliance with insider-trading rules.
The filing explicitly states the sales were effected pursuant to a Rule 10b5-1 plan covering equity grants expiring before August 21, 2025. That procedural detail reduces regulatory risk from timing allegations. The report also documents remaining equity holdings and vested options, supporting transparent disclosure of the directors beneficial ownership and post-transaction option balances.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to buy) | 19,200 | $0.00 | -- |
| Exercise | Common Stock | 19,200 | $7.20 | $138K |
| Sale | Common Stock | 19,200 | $15.8422 | $304K |
| Exercise | Stock Options (Right to buy) | 14,400 | $0.00 | -- |
| Exercise | Stock Options (Right to buy) | 4,800 | $0.00 | -- |
| Exercise | Common Stock | 19,200 | $7.20 | $138K |
| Sale | Common Stock | 19,200 | $15.5421 | $298K |
| Exercise | Stock Options (Right to buy) | 19,200 | $0.00 | -- |
| Exercise | Common Stock | 19,200 | $7.20 | $138K |
| Sale | Common Stock | 19,200 | $14.1938 | $273K |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to August 21, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 135,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock. The sale prices ranged from $13.30 to $14.80. The sale prices ranged from $14.88 to $15.91. The sale prices ranged from $15.61 to $16.00. This option is fully vested.
